Asset Details
Do you wish to reserve the book?
Organ‐Specific Dedifferentiation and Epigenetic Remodeling in In Vivo Reprogramming
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Organ‐Specific Dedifferentiation and Epigenetic Remodeling in In Vivo Reprogramming
Do you wish to request the book?
Organ‐Specific Dedifferentiation and Epigenetic Remodeling in In Vivo Reprogramming
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Organ‐Specific Dedifferentiation and Epigenetic Remodeling in In Vivo Reprogramming
2025
Overview
The advent of in vivo reprogramming through transient expression of the Yamanaka factors (OCT4, SOX2, KLF4, and c‐MYC) holds strong promise for regenerative medicine, despite ongoing concerns about safety and clinical applicability. This review synthesizes recent advances in in vivo reprogramming, focusing on its potential to restore regenerative competence and promote rejuvenation across diverse tissues, including the retina, skeletal muscle, heart, liver, brain, and intestine. We highlight mechanistic parallels and distinctions between injury‐induced dedifferentiation and OSKM‐mediated reprogramming, emphasizing the roles of dedifferentiation, transient regenerative progenitors, and epigenetic remodeling. Critical safety considerations—such as teratoma formation, organ failure, and loss of cell identity—are discussed alongside strategies designed to mitigate these risks, like cyclic induction and targeted delivery. Finally, we briefly note the growing translational interest in this field, alongside directing readers to recent reviews for detailed coverage of biotech initiatives. Collectively, this work underscores the transformative potential of in vivo reprogramming for both tissue regeneration and rejuvenation, while stressing the importance of precise spatiotemporal control for its safe clinical application. Transient in vivo expression of Yamanaka factors (OSKM) enhances regenerative competence and rejuvenation across multiple tissues. We highlight mechanistic links between injury‐induced dedifferentiation and OSKM reprogramming, while emphasizing safety challenges and the need for precise spatiotemporal control to enable clinical translation.
Publisher
John Wiley & Sons, Inc,Wiley
